

Charles J Ryan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3392194/publications.pdf>

Version: 2024-02-01

91
papers

10,883
citations

159358

30
h-index

49773

87
g-index

92
all docs

92
docs citations

92
times ranked

10219
citing authors

#	ARTICLE	IF	CITATIONS
1	Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?. <i>Cancers</i> , 2022, 14, 801.	1.7	23
2	Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 86-92.	2.0	23
3	Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS194-TPS194.	0.8	2
4	A phase II trial of abemaciclib (abema) and atezolizumab (atezo) in unselected and <i>CDK12</i> -loss metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS213-TPS213.	0.8	2
5	Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 287-287.	0.8	2
6	Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4-4.	0.8	2
7	Molecular and immune landscape of <i>FH</i> -mutated kidney cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 382-382.	0.8	0
8	A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1531-1539.	3.2	9
9	Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. <i>CNS Drugs</i> , 2022, 36, 419-449.	2.7	6
10	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. <i>European Journal of Cancer</i> , 2022, 170, 296-304.	1.3	14
11	Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer. <i>Endocrine Oncology</i> , 2022, 2, R51-R64.	0.1	1
12	Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5107-TPS5107.	0.8	1
13	Resetting the Bar of Castration Resistance — Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 199-207.	0.9	7
14	Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data. <i>Current Medical Research and Opinion</i> , 2021, 37, 609-622.	0.9	12
15	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 25-25.	0.8	2
16	Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5063-5063.	0.8	1
17	Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 986-996.	2.0	8
18	A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5043-5043.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. <i>Journal of Urology</i> , 2021, 206, 1420-1429.	0.2	24
20	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021, 30, 47-62.	0.2	2
21	Efficacy and Adverse Events of Docetaxel for Metastatic, Hormone-sensitive Prostate Cancer Among Elderly Men: A Post Hoc Analysis of the CHAARTED Trial. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 388-395.	0.9	2
22	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	3.2	12
23	Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-Intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 8058-8070.	1.3	11
24	Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 66-73.	2.0	9
25	Diet and lifestyle considerations for patients with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 105-117.	0.8	36
26	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	0.8	24
27	Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 222-229.e2.	0.9	5
28	A review of prostate cancer treatment impact on the CNS and cognitive function. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 207-219.	2.0	59
29	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	1.4	35
30	Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. <i>ESMO Open</i> , 2020, 5, e000943.	2.0	2
31	Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians. <i>Prostate</i> , 2020, 80, 1159-1176.	1.2	11
32	Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 793.e1-793.e11.	0.8	7
33	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	0.8	448
34	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. <i>Cancers</i> , 2020, 12, 2659.	1.7	54
35	Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types. <i>ESMO Open</i> , 2020, 5, e000803.	2.0	18
36	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12315-12323.	3.3	87

#	ARTICLE	IF	CITATIONS
37	Addressing Cardiovascular Risk of Prostate Cancer Hormonal Therapy. <i>JACC: CardioOncology</i> , 2020, 2, 82-83.	1.7	2
38	Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US).. <i>Journal of Clinical Oncology</i> , 2020, 38, e19131-e19131.	0.8	9
39	Association of polymorphisms in androgen production, uptake, and conversion chain (APUC) genes with mortality of prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5528-5528.	0.8	0
40	Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in , and on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2020, 8, 106-115.	0.4	2
41	Hard Problems Need "Soft" Science: Integrating Quality of Life into Treatment Decision Making. <i>European Urology</i> , 2019, 75, 948-949.	0.9	3
42	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 275-282.e1.	0.9	42
43	Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 309-320.	1.8	42
44	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. <i>European Journal of Cancer</i> , 2019, 114, 107-116.	1.3	42
45	How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100476.	0.5	10
46	Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs. <i>Oncologist</i> , 2019, 24, 291-292.	1.9	5
47	Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer. <i>Cancer</i> , 2019, 125, 453-462.	2.0	13
48	Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 184-190.e2.	0.9	13
49	A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone-and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2018, 23, 656-e64.	1.9	25
50	<i>HSD3B1</i> and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 554.	3.4	48
51	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. <i>BMJ Open</i> , 2018, 8, e022899.	0.8	85
52	Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 1344.	3.4	169
53	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	13.5	459
54	Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways. <i>Annals of Translational Medicine</i> , 2018, 6, 161-161.	0.7	7

#	ARTICLE	IF	CITATIONS
55	A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 60-67.	0.5	10
56	BRCAness and prostate cancer: diagnostic and therapeutic considerations. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 488-498.	2.0	12
57	A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 149.e7-149.e13.	0.8	7
58	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	3.4	219
59	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 999-1005.	7.7	223
60	High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 733-741.e1.	0.9	16
61	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. <i>Lancet Oncology</i> , The, 2017, 18, 132-142.	5.1	124
62	Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 5-7.	0.6	2
63	Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. <i>European Urology</i> , 2016, 70, 963-970.	0.9	104
64	Utility of novel androgen receptor therapies in the real world: A nuanced approach. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 340-347.	0.8	2
65	DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. <i>Oncologist</i> , 2016, 21, 940-945.	1.9	29
66	Targeting the Androgen Receptor: Remaining questions and future directions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 339.	0.8	0
67	Approaches to minimize castration in the treatment of advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 368-374.	0.8	6
68	Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2015, 3, 1008-1016.	1.6	49
69	Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens. <i>Clinical Cancer Research</i> , 2014, 20, 6269-6276.	3.2	32
70	Bone-Targeting Radiopharmaceuticals for the Treatment of Bone-Metastatic Castration-Resistant Prostate Cancer: Exploring the Implications of New Data. <i>Oncologist</i> , 2014, 19, 1012-1018.	1.9	14
71	Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 1143-1150.	0.8	217
72	Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). <i>European Urology</i> , 2014, 66, 815-825.	0.9	221

#	ARTICLE	IF	CITATIONS
73	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1193-1199.	5.1	142
74	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	13.9	2,412
75	Abiraterone acetate for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 91-96.	0.9	29
76	Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3621-3630.	3.2	350
77	Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2791-2798.	0.8	111
78	Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1995-2005.	13.9	3,736
79	Phase II Study of Abiraterone Acetate in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response. <i>Clinical Cancer Research</i> , 2011, 17, 4854-4861.	3.2	203
80	Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1481-1488.	0.8	369
81	Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF1 receptor and androgen dependent growth of LAPC prostate cancer cells. <i>Prostate</i> , 2008, 68, 1232-1240.	1.2	15
82	Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study. <i>Clinical Cancer Research</i> , 2007, 13, 2030-2037.	3.2	85
83	Phase II Study of Ketoconazole Plus Granulocyte-Macrophage Colony-Stimulating Factor for Prostate Cancer: Effect of Extent of Disease on Outcome. <i>Journal of Urology</i> , 2007, 178, 2372-2377.	0.2	21
84	Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). <i>Investigational New Drugs</i> , 2007, 25, 445-451.	1.2	70
85	Secondary Hormonal Manipulations in Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 925-934.	0.9	5
86	Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 250-253.	0.8	35
87	Prostate cancer update: 2005. <i>Current Opinion in Oncology</i> , 2006, 18, 284-288.	1.1	15
88	Progress in detection and treatment of prostate cancer. <i>Current Opinion in Internal Medicine</i> , 2005, 4, 416-419.	1.5	3
89	The Selection of Hormonal Therapy in Prostate Cancer: Who, When, and for How Long?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2, 261-268.	2.3	1
90	Advances in prostate cancer. <i>Current Opinion in Oncology</i> , 2004, 16, 242-246.	1.1	12

#	ARTICLE	IF	CITATIONS
91	Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology, 2003, 62, 87-94.	0.5	45